Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Tuesday, March 24, 2015

Cannabis use lowers risk for insulin resistance in patients with HIV/HCV

Among patients coinfected with HIV and hepatitis C, cannabis use reduced the risk for insulin resistance, according to researchers from INSERM in France.

“This is the first longitudinal study documenting the relationship between the reduced risk of insulin resistance and cannabis use in a population particularly concerned by insulin resistance risk,” the researchers wrote in Clinical Infectious Diseases. “The results found were robust as they were confirmed in three sensitivity analyses, one of [these] also including patients with diabetes.”

M. Patrizia Carrieri, PhD, and colleagues evaluated data from the ANRS HEPAVIH CO-13 cohort, which included patients in France coinfected with HIV and HCV. The data included patient information obtained from self-administered questionnaires, such as HIV and HCV testing, HIV-related symptoms, coffee consumption and drug and alcohol use in the previous month. The questionnaires were completed every 12 months for 60 months.

Read more...

No comments:

Post a Comment